Farmatek

Company snapshot

Farmatek®, Tuzla Kimya Sanayicileri Organize Sanayi Bölgesi'nde kurulu, GMP sertifikalı tesisinde Veteriner Dış Parazit ürünleri ve haşere mücadelesinde kullanılan Biyosidal formülasyonları üretir. Farmatek®, veteriner ilaçları ve biyosidal formülasyonlar segmentinde faaliyet gösteren firmalara fason üretim hizmeti veren, sektöründe öncü bir çözüm ortağıdır. ** Farmatek® produces veterinary ectopa

• 26 active pipeline program(s) linked via ClinicalTrials.gov.
• 53 US patent(s) indexed to this assignee profile.
• 26 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Farmatek. Not investment advice.

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  Eikon Therapeutics

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Farmatek.

1. Jun 8, 2026 Clinical update

   MINOCIN 100 mg capsule rigide — Phase 2

2. Jun 8, 2026 Clinical update

   FT819 — Phase 1

3. Jun 8, 2026 Clinical update

   FT576 (Allogenic CAR NK cells with BCMA expression) — Phase 1

4. Jun 8, 2026 Clinical update

   Fludarabine — Phase 1

5. Jun 8, 2026 Clinical update

   Biological: ProHema-CB — Phase 1

View all clinical trial activity →

• What is Farmatek?

  Farmatek is a pharma organization headquartered in Istanbul, JP. Primary therapeutic focus areas include Hematologic Malignancies, Solid Tumor, Adult, Lymphoma, B-Cell, B-cell Mediated Autoimmune Diseases, COPD. NovaPharmaNews links 26 clinical program(s), 0 drug profile(s), and

• Is Farmatek publicly traded?

  Farmatek appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Farmatek develop or market?

  We link 14 drug profile(s) where Farmatek is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/fate-therapeutics-inc#company-drugs.

• What are the latest developments for Farmatek?

  In the last 12 months our linked public records show 26 trial program update(s) and 4 US patent grant(s) tied to this profile.

• What therapeutic areas does Farmatek focus on?

  Farmatek focuses on Hematologic Malignancies, Solid Tumor, Adult, Lymphoma, B-Cell based on our analysis of their pipeline programs and drug development activities.